Results 41 to 50 of about 4,786,755 (237)

Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection? [PDF]

, 2012
Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Grützmacher, Peter, Oliver Jung, Christoph Stephan, Markus Bickel, Peter Gruetzmacher, Kerstin Amann, Hans Stefan Haack, Jung, Oliver, Haack, Hans Stefan, Büttner, Maike, Stephan, Christoph, Bickel, Markus, Amann, Kerstin, Amann, Kerstin Ute, Betz, Christoph, Maike Buettner, Haack, Hans S., Christoph Betz   +17 more
core   +2 more sources

Immunoglobulin light chain amyloidosis [PDF]

memo - Magazine of European Medical Oncology, 2021
SummaryImmunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains. The monoclonal light chain paraprotein originates from a small clonal B‑cell or a clonal plasma cell population.
Hermine Agis, Maria T. Krauth
openaire   +1 more source

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis [PDF]

Journal of Clinical Oncology, 2020
PURPOSE Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex).
Kastritis, Efstathios, Leleu, Xavier, Arnulf, Bertrand, Zamagni, Elena, Cibeira, Maria Teresa, Kwok, Fiona, Mollee, Peter, Hajek, Roman, Moreau, Philippe, Jaccard, Arnaud, Schonland, Stefan O., Filshie, Robin, Nicolas-Virelizier, Emmanuelle, Augustson, Bradley, Mateos, Maria-Victoria, Wechalekar, Ashutosh, Hachulla, Eric, Milani, Paolo, Dimopoulos, Meletios A., Fermand, Jean-Paul, Foli, Andrea, Gavriatopoulou, Maria, Klersy, Catherine, Palumbo, Antonio, Sonneveld, Pieter, Johnsen, Hans Erik, Merlini, Giampaolo, Palladini, Giovanni   +27 more
openaire   +11 more sources

Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST)

Journal of the Formosan Medical Association
Light chain (AL) amyloidosis, defined by the organ deposition of misfolded and aggregated amyloid light chain, is the most common subtype of systematic amyloidosis with an incidence rate of around 1 case per 100,000 person-years in Taiwan.
Yen-Wen Wu, Chao-Hung Wei, Yen-Hung Lin, Shang-Yi Huang, Yen-Wen Liu, Tran-Der Tan, Wen-Chung Yu, Chia-Jen Liu, Chung-Lieh Hung, Po-Shen Ko, Ning-I Yang, Shih-Feng Cho, Chun-Yao Huang, Chun-Kai Liao, Chieh-Lin Jerry Teng, Tsai-Yun Chen, Wen-Jone Chen, Bor-Sheng Ko   +17 more
doaj   +1 more source

Idiopathic membranous nephropathy with renal amyloidosis: A case report

Frontiers in Medicine, 2022
BackgroundImmunoglobulin light chain amyloidosis is a clonal, non-proliferative plasma cell disorder, in which fragments of immunoglobulin light chain are deposited in tissues.
Yue Wang, Xueyao Wang, Jinyu Yu, Shan Wu, Zhonggao Xu, Weixia Sun   +5 more
doaj   +1 more source

Duodenal biopsy: an unexpected confirmatory test for a patient with al-amyloidosis

Sri Lanka Journal of Medicine, 2019
SSystemic AL- amyloidosis is a disorder of protein folding in which there is extra-cellular accumulation as β pleated fibrillar deposits of monoclonal immunoglobulin light chain fragments. AL- amyloidosis is a rare clinical entity.
S. Pirasath, T. Kumanan, G. Selvaratnam, V. Sujanitha, D. D. Dikowita   +4 more
doaj   +1 more source

Light‐chain amyloid myopathy isolated to skeletal muscles: A case report

Clinical Case Reports, 2020
Isolated amyloidosis, especially of amyloid light‐chain type, is an infrequent disease. Systemic chemotherapy for light‐chain amyloidosis isolated to skeletal muscles plays a key role to reduce clonal plasma cells producing aberrant immunoglobulin.
Toshihiro Matsukawa, Katsuki Eguchi, Ichizo Nishino, Kohei Okada, Kazuo Oshimi, Takuto Miyagishima   +5 more
doaj   +1 more source

Light chain amyloidosis [PDF]

, 2021
Light chain amyloidosis (AL) is the most common subtype of amyloidosis except wild type tranthyretine amyloidosis and is caused by the deposition of misfolded monoclonal light chains of immunoglobulins produced by a monoclonal B cell, mainly of plasma ...
PIROTTE, Michelle, Rizzo, Ornella, Roussel, Murielle, Jaccard, Arnaud   +3 more
core  

Virtual Screening for Promising Kinetic Stabilizers of Light Chains in Immunoglobulin Light Chain Amyloidosis Through Drug Repurposing [PDF]

, 2023
In immunoglobulin light chain amyloidosis, unstable immunoglobulin light chains aggregate as amyloid fibrils in organs, leading to organ failure and death in more than 50% of untreated patients. Research by Morgan et al. (Morgan, G. J. et.
Jonas, Jeppesen, Jeppesen, Jonas B, Casper, Steinmann, Steinmann, Casper; id_orcid   +3 more
core   +2 more sources

Systemic Light Chain Amyloidosis Mimicking Rheumatic Disorders [PDF]

, 2016
Secondary amyloidosis can complicate chronic inflammatory autoimmune diseases. However, the clinical findings of primary amyloidosis may mimic those of primary rheumatologic disorders.
Wai Chung Yong, Mary Chester Wasko, Rohit R. Rao   +2 more
core   +1 more source